Oral drug delivery research in Europe

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 247-253

  Mrsny, Randall J ^a  

^a University of Bath   (United Kingdom)

Author keywords

Drug solubility; Drug stability; Nanomaterials; Oral drug delivery

Indexed keywords

BIOLOGICAL BARRIER; DECISION MAKERS; DRUG SOLUBILITY; DRUG STABILITY; ORAL ADMINISTRATION; ORAL DELIVERY; ORAL DRUG DELIVERY; PHARMACEUTICAL INDUSTRY;

BIOCHEMISTRY; NANOSTRUCTURED MATERIALS;

DRUG DELIVERY;

ALGINIC ACID; CYCLODEXTRIN; CYCLOSPORIN A; EUDRAGIT; LIPOSOME; NANOMATERIAL; SALCATONIN;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; EUROPE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH PH;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOMEDICAL RESEARCH; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EUROPE; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84862684767     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.01.017     Document Type: Review

References (81)

1. B.G. Gimenez, M.S. Santos, M. Ferrarini, J.P. Fernandes, Evaluation of blockbuster drugs under the rule-of-five, Pharmazie 65 (2010) 148-152.
2. J.W. Davies, M. Glick, J.L. Jenkins, Streamlining lead discovery by aligning in silico and high-throughput screening, Curr. Opin. Chem. Biol. 10 (2006) 343-351.
3. M. Orita, K. Ohno, M. Warizaya, Y. Amano, T. Niimi, Lead generation and examples opinion regarding how to follow up hits, Methods Enzymol. 493 (2011) 383-419.
4. M.N. Schulz, R.E. Hubbard, Recent progress in fragment-based lead discovery, Curr. Opin. Pharmacol. 9 (2009) 615-621.
5. T. Wunberg, M. Hendrix, A. Hillisch, M. Lobell, H. Meier, C. Schmeck, H. Wild, B. Hinzen, Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits, Drug Discov. Today 11 (2006) 175-180.
6. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, F. Misselwitz, The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor, Nat. Rev. Drug Discov. 10 (2011) 61-75.
7. B.A. Kenny, M. Bushfield, D.J. Parry-Smith, S. Fogarty, J.M. Treherne, The application of high-throughput screening to novel lead discovery, Prog. Drug Res. 51 (1998) 245-269.
8. R. Sink, S. Gobec, S. Pecar, A. Zega, False positives in the early stages of drug discovery, Curr. Med. Chem. 17 (2010) 4231-4255.
9. A. Bernkop-Schnurch, T. Schmitz, Presystemic metabolism of orally administered peptide drugs and strategies to overcome it, Curr. Drug Metab. 8 (2007) 509-517.
10. D.J. Brayden, R.J. Mrsny, Oral delivery of macromolecules: Pprioritizing the leading technologies, Therap. Del. (in press).
11. P. Prinderre, C. Sauzet, C. Fuxen, Advances in gastro retentive drug-delivery systems, Expert Opin. Drug Deliv. 8 (2011) 1189-1203.
12. O.A. Abu-Diak, D.S. Jones, G.P. Andrews, An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations, Mol. Pharm. 8 (2011) 1362-1371.
13. I. Erel, H. Schlaad, A.L. Demirel, Effect of structural isomerism and polymer end group on the pH-stability of hydrogen-bonded multilayers, J. Colloid Interface Sci. 361 (2011) 477-482.
14. R. Negrini, R. Mezzenga, pH-responsive lyotropic liquid crystals for controlled drug delivery, Langmuir 27 (2011) 5296-5303.
15. E. Gavini, G. Spada, G. Rassu, G. Cerri, A. Brundu, M. Cossu, M. Sorrenti, P. Giunchedi, Development of solid nanoparticles based on hydroxypropyl-beta-cyclodextrin aimed for the colonic transmucosal delivery of diclofenac sodium, J. Pharm. Pharmacol. 63 (2011) 472-482.
16. M.J. Barea, M.J. Jenkins, M.H. Gaber, R.H. Bridson, Evaluation of liposomes coated with a pH responsive polymer, Int. J. Pharm. 402 (2010) 89-94.
17. C.M. Cassidy, M.M. Tunney, D.L. Caldwell, G.P. Andrews, R.F. Donnelly, Development of novel oral formulations prepared via hot melt extrusion for targeted delivery of photosensitizer to the colon, Photochem. Photobiol. 87 (2011) 867-876.
18. A. Dalmoro, G. Lamberti, G. Titomanlio, A.A. Barba, M. d'Amore, Enteric microparticles for targeted oral drug delivery, AAPS PharmSciTech 11 (2010) 1500-1507.
19. F. Eisenacher, A. Schadlich, K. Mader, Monitoring of internal pH gradients within multi-layer tablets by optical methods and EPR imaging, Int. J. Pharm. 417 (2011) 204-215.
20. H.A. Merchant, E.L. McConnell, F. Liu, C. Ramaswamy, R.P. Kulkarni, A.W. Basit, S. Murdan, Assessment of gastrointestinal pH, fluid and lymphoid tissue in the guinea pig, rabbit and pig, and implications for their use in drug development, Eur. J. Pharm. Sci. 42 (2011) 3-10.
21. M. Vialpando, A. Aerts, J. Persoons, J. Martens, G. Van Den Mooter, Evaluation of orderedmesoporous silica as a carrier for poorly soluble drugs: influence of pressure on the structure and drug release, J. Pharm. Sci. 100 (2011) 3411-3420.
22. M.E. Morales, G. Lopez, V. Gallardo, M.A. Ruiz, Oral suspensions of morphine hydrochloride for controlled release: rheological properties and drug release, Mol. Pharm. 8 (2011) 629-634.
23. G. Frutos, A. Prior-Cabanillas, R. Paris, I. Quijada-Garrido, A novel controlled drug delivery systembased on pH-responsive hydrogels included in soft gelatin capsules, Acta Biomater. 6 (2010) 4650-4656.
24. N. Passerini, B. Perissutti, B. Albertini, E. Franceschinis, D. Lenaz, D. Hasa, I. Locatelli, D. Voinovich, A new approach to enhance oral bioavailability of Silybum Marianum dry extract: association of mechanochemical activation and spray congealing, Phytomedicine 19 (2012) 160-168.
25. V. Iannuccelli, M. Montanari, D. Bertelli, F. Pellati, G. Coppi, Microparticulate polyelectrolyte complexes for gentamicin transport across intestinal epithelia, Drug Deliv. 18 (2011) 26-37.
26. J. Tokarsky, T. Andrysek, P. Capkova, Molecular modeling of gel nanoparticles with cyclosporine A for oral drug delivery, Int. J. Pharm. 410 (2011) 196-205.
27. J. Iqbal, F. Sarti, G. Perera, A. Bernkop-Schnurch, Development and in vivo evaluation of an oral drug delivery system for paclitaxel, Biomaterials 32 (2011) 170-175.
28. S. Charef, D. Papy-Garcia, J. Courty, Absorption and tissue distribution of a novel carboxymethyldextran after oral administration, Biomed. Pharmacother. 64 (2010) 627-632.
29. J.M.Mason, Design and development of peptides and peptidemimetics as antagonists for therapeutic intervention, Future Med. Chem. 2 (2010) 1813-1822.
30. K. Bellmann-Sickert, A.G. Beck-Sickinger, Peptide drugs to target G protein-coupled receptors, Trends Pharmacol. Sci. 31 (2010) 434-441.
31. D. Fernandez, E. Boix, I. Pallares, F.X. Aviles, J. Vendrell, Structural and functional analysis of the complex between citrate and the zinc peptidase carboxypeptidase A, Enzyme Res. 2011 (2011) 128676.
32. A. Mullertz, A. Ogbonna, S. Ren, T. Rades, New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs, J. Pharm. Pharmacol. 62 (2010) 1622-1636.
33. J.A. Yanez, S.W. Wang, I.W. Knemeyer, M.A. Wirth, K.B. Alton, Intestinal lymphatic transport for drug delivery, Adv. Drug Deliv. Rev. 63 (2011) 923-942.
34. T. Loftsson, M.E. Brewster, Pharmaceutical applications of cyclodextrins: basic science and product development, J. Pharm. Pharmacol. 62 (2010) 1607-1621.
35. M. Hamoudi, E. Fattal, C. Gueutin, V. Nicolas, A. Bochot, Beads made of cyclodextrin and oil for the oral delivery of lipophilic drugs: in vitro studies in simulated gastro-intestinal fluids, Int. J. Pharm. 416 (2011) 507-514.
36. L.M. Bimbo, E. Makila, T. Laaksonen, V.P. Lehto, J. Salonen, J. Hirvonen, H.A. Santos, Drug permeation across intestinal epithelial cells using porous silicon nanoparticles, Biomaterials 32 (2011) 2625-2633.
37. J. Parmentier, M.M. Becker, U. Heintz, G. Fricker, Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids, Int. J. Pharm. 405 (2011) 210-217.
38. M. Muchow, P. Maincent, R.H. Muller, C.M. Keck, Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement, Drug Dev. Ind. Pharm. 37 (2011) 8-14.
39. G. Mittal, H. Carswell, R. Brett, S. Currie, M.N. Kumar, Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology, J. Control. Release 150 (2011) 220-228.
40. J. Parmentier, F.J. Hartmann, G. Fricker, In vitro evaluation of liposomes containing bio-enhancers for the oral delivery of macromolecules, Eur. J. Pharm. Biopharm. 76 (2010) 394-403.
41. C.B. Woitiski, R.J. Neufeld, F. Veiga, R.A. Carvalho, I.V. Figueiredo, Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles, Eur. J. Pharm. Sci. 41 (2010) 556-563.
42. S. Rujivipat, R. Bodmeier, Modified release from hydroxypropyl methylcellulose compression-coated tablets, Int. J. Pharm. 402 (2010) 72-77.
43. S.A. Ferreira, P. Pereira, P. Sampaio, P.J. Coutinho, F.M.Gama, Supramolecular assembled nanogel made of mannan, J. Colloid Interface Sci. 361 (2011) 97-108.
44. C. Thompson, W.P. Cheng, P. Gadad, K. Skene, M. Smith, G. Smith, A. McKinnon, R. Knott, Uptake and transport of novel amphiphilic polyelectrolyte-insulin nanocomplexes by Caco-2 cells-towards oral insulin, Pharm. Res. 28 (2011) 886-896.
45. L. Plapied, G. Vandermeulen, B. Vroman, V. Preat, A. des Rieux, Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery, Int. J. Pharm. 398 (2010) 210-218.
46. B. Devriendt, B.G. De Geest, E. Cox, Designing oral vaccines targeting intestinal dendritic cells, Expert Opin. Drug Deliv. 8 (2011) 467-483.
47. E.Wenk,H.P.Merkle, L.Meinel, Silk fibroin as a vehicle for drug delivery applications, J. Control. Release 150 (2011) 128-141.
48. C. Schleh, M. Semmler-Behnke, J. Lipka, A. Wenk, S. Hirn, M. Sch Ffler, G.N. Schmid, U. Simon, W.G. Kreyling, Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration, Nanotoxicology 6 (2012) 36-46.
49. J. Iqbal, C. Vigl, G. Moser, M. Gasteiger, G. Perera, A. Bernkop-Schnurch, Development and in vivo evaluation of a new oral nanoparticulate dosage form for leuprolide based on polyacrylic acid, Drug Deliv. 18 (2011) 432-440.
50. D.D. Ankola, R.M. Wadsworth, M.N. Ravi Kumar, Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage, J. Biomed. Nanotechnol. 7 (2011) 300-307.
51. V. Hearnden, V. Sankar, K. Hull, D.V. Juras, M. Greenberg, A.R. Kerr, P.B. Lockhart, L.L. Patton, S. Porter, M.H. Thornhill, New developments and opportunities in oral mucosal drug delivery for local and systemic disease, Adv. Drug Deliv. Rev. 64 (2012) 16-28.
52. V.F. Patel, F. Liu, M.B. Brown, Advances in oral transmucosal drug delivery, J. Control. Release 153 (2011) 106-116.
53. X. Qi, R.F. Tester, Bioadhesive properties of beta-limit dextrin, J. Pharm. Pharm. Sci. 14 (2011) 60-66.
54. M.J. Santander-Ortega, J.M. Peula-Garcia, F.M. Goycoolea, J.L. Ortega-Vinuesa, Chitosan nanocapsules: effect of chitosan molecular weight and acetylation degree on electrokinetic behaviour and colloidal stability, Colloids Surf. B Biointerfaces 82 (2011) 571-580.
55. B. Calija, N. Cekic, S. Savic, D. Krajisnik, R. Daniels, J. Milic, An investigation of formulation factors affecting feasibility of alginate-chitosan microparticles for oral delivery of naproxen, Arch. Pharm. Res. 34 (2011) 919-929.
56. D. Sakloetsakun, G. Perera, J. Hombach, G.Millotti, A. Bernkop-Schnurch, The impact of vehicles on themucoadhesive properties of orally administrated nanoparticles: a case study with chitosan-4-thiobutylamidine conjugate, AAPS PharmSciTech 11 (2010) 1185-1192.
57. G. Millotti, G. Perera, C. Vigl, K. Pickl, F.M. Sinner, A. Bernkop-Schnurch, The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery, Drug Deliv. 18 (2011) 190-197.
58. M. Agueros, S. Espuelas, I. Esparza, P. Calleja, I. Penuelas, G. Ponchel, J.M. Irache, Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery, Expert Opin. Drug Deliv. 8 (2011) 721-734.
59. J. Calvo, J.L. Lavandera, M. Agueros, J.M. Irache, Cyclodextrin/ poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone, Biomed. Microdevices 13 (2011) 1015-1025.
60. D. Teutonico, S. Montanari, G. Ponchel, Concentration and surface of absorption: concepts and applications to gastrointestinal patches delivery, Int. J. Pharm. 413 (2011) 87-92.
61. D. Teutonico, G. Ponchel, Patches for improving gastrointestinal absorption: an overview, Drug Discov. Today 16 (2011) 991-997.
62. G. Sharma, K. Wilson, C.F. van der Walle, N. Sattar, J.R. Petrie, M.N. Ravi Kumar, Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats, Eur. J. Pharm. Biopharm. 76 (2010) 159-169.
63. K. Henriksen, A.C. Bay-Jensen, C. Christiansen, M.A. Karsdal, Oral salmon calcitonin-pharmacology in osteoporosis, Expert Opin. Biol. Ther. 10 (2010) 1617-1629.
64. M.A. Karsdal, K. Henriksen, A.C. Bay-Jensen, B. Molloy, M. Arnold, M.R. John, I. Byrjalsen, M. Azria, B.J. Riis, P. Qvist, C. Christiansen, Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials, J. Clin. Pharmacol. 51 (2011) 460-471.
65. W.P. Cheng, C. Thompson, S.M. Ryan, T. Aguirre, L. Tetley, D.J. Brayden, In vitro and in vivo characterisation of a novel peptide delivery system: amphiphilic polyelectrolyte-salmon calcitonin nanocomplexes, J. Control. Release 147 (2010) 289-297.
66. R.E. Steinert, B. Poller, M.C. Castelli, J. Drewe, C. Beglinger, Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects, Am. J. Clin. Nutr. 92 (2010) 810-817.
67. M.D. Del Curto, A. Maroni, L. Palugan, L. Zema, A. Gazzaniga, M.E. Sangalli, Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor/absorption enhancer compounds, J. Pharm. Sci. 100 (2011) 3251-3259.
68. V. Mamaeva, J.M. Rosenholm, L.T. Bate-Eya, L. Bergman, E. Peuhu, A. Duchanoy, L.E. Fortelius, S. Landor, D.M. Toivola, M. Linden, C. Sahlgren, Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of notch signaling in cancer, Mol. Ther. 19 (2011) 1538-1546.
69. G. Muller, Oral delivery of protein drugs: driver for personalized medicine, Curr. Issues Mol. Biol. 13 (2010) 13-24.
70. A. Maroni, L. Zema, M.D. Del Curto, G. Loreti, A. Gazzaniga, Oral pulsatile delivery: rationale and chronopharmaceutical formulations, Int. J. Pharm. 398 (2010) 1-8.
71. K. Wening, J. Breitkreutz, Oral drug delivery in personalized medicine: unmet needs and novel approaches, Int. J. Pharm. 404 (2011) 1-9.
72. K. Wening, J. Breitkreutz, Novel delivery device for monolithical solid oral dosage forms for personalized medicine, Int. J. Pharm. 395 (2010) 174-181.
73. M. Grassi, G. Lamberti, S. Cascone, G. Grassi, Mathematical modeling of simultaneous drug release and in vivo absorption, Int. J. Pharm. 418 (2011) 130-141.
74. N. Fotaki, M. Vertzoni, Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations, Open Drug Deliv. J. 4 (2010) 2-13.
75. N. Fotaki, A. Aivaliotis, J. Butler, J. Dressman, M. Fischbach, J. Hempenstall, S. Klein, C. Reppas, A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations, Eur. J. Pharm. Biopharm. 73 (2009) 115-120.
76. G. Garbacz, S. Klein, W. Weitschies, A biorelevant dissolution stress test device - background and experiences, Expert Opin. Drug Deliv. 7 (2010) 1251-1261.
77. W. Weitschies, C.G. Wilson, In vivo imaging of drug delivery systems in the gastrointestinal tract, Int. J. Pharm. 417 (2011) 216-226.
78. A. Stockis, M.L. Sargentini-Maier, C. Otoul, A. Connor, I. Wilding, H. Wray, Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: open-label, single-dose, randomized, four-way crossover study in healthy male volunteers, Clin. Ther. 32 (2010) 1813-1821.
79. C.C. Wagner, A. Rusca, K. Kletter, M. Tschurlovits, S. Pace, A. Longo, M. Pedrani, R. Villa, E. Frimonti, M. Muller, M. Brunner, Plasma pharmacokinetics and gastrointestinal transit of a new Propionyl-l-Carnitine controlled release formulation, Xenobiotica 41 (2011) 988-995.
80. A. Almeida, S. Possemiers, M.N. Boone, T. De Beer, T. Quinten, L. Van Hoorebeke, J.P. Remon, C. Vervaet, Ethylene vinyl acetate as matrix for oral sustained release dosage forms produced via hot-melt extrusion, Eur. J. Pharm. Biopharm. 77 (2011) 297-305.
81. J.L. Kaye, Review of paediatric gastrointestinal physiology data relevant to oral drug delivery, Int. J. Clin. Pharmacol. 33 (2011) 20-24.